<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61341">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307370</url>
  </required_header>
  <id_info>
    <org_study_id>D024204</org_study_id>
    <nct_id>NCT02307370</nct_id>
  </id_info>
  <brief_title>Atherectomy By Laser Ablation With Turbo-Elite</brief_title>
  <acronym>ABLATE</acronym>
  <official_title>Atherectomy By Laser Ablation With Turbo-Elite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectranetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectranetics Corporation</source>
  <brief_summary>
    <textblock>
      The primary objective for this study is to prove the safety and effectiveness of the
      Spectranetics Turbo-Elite catheter in atherectomy treatment for infrainguinal arteries with
      catheter to vessel sizing of at least 50%.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint (Mean reduction in percent stenosis of greater than 20% by angiographic core lab assessment)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint (80% freedom from MAE, all cause death, major amputation in target limb, or TLR)</measure>
    <time_frame>30 day follow-up</time_frame>
    <description>80% freedom from MAE, all cause death, major amputation in target limb, or TLR</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Turbo-Elite Atherectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Turbo-Elite Laser Catheter</intervention_name>
    <description>Application of laser energy to remove blockage</description>
    <arm_group_label>Turbo-Elite Atherectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PAD with Rutherford Class 1-4

          -  Patient is able to walk unassisted or with non-motorized assistive devices.

          -  Documented PAD by ABI &lt;0.9 or previous intervention with reoccurrence of symptoms

          -  Documented stenosis by duplex ≥50%

        Exclusion Criteria:

          -  Patient is pregnant or breast feeding.

          -  Evidence of Acute Limb Ischemia within 7 days prior to procedure.

          -  CVA &lt; 60 days prior to procedure.

          -  MI &lt; 60 days prior to procedure.

          -  Known contraindication to aspirin, antiplatelet/anti-coagulant therapies required for
             procedure/follow up.

          -  Known allergy to contrast media that cannot adequately be pre-medicated prior to
             study procedure.

          -  Uncontrolled hypercoagulability or history of HIT or HITTS syndrome.

          -  Serum creatinine ≥ 2.5 mg/dL (unless dialysis-dependent) within one day prior to
             procedure.

          -  Patient is simultaneously participating in another investigational drug or device
             study that will interfere with the 30 day Safety Endpoint.

          -  Previously identified severe calcium in the vessel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 12, 2016</lastchanged_date>
  <firstreceived_date>November 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
